Exelixis | EXEL - Operating Profit


Exelixis reported $256.36M in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
Acadia Pharmaceuticals USD 35.76M 3.38M Sep/2025
Agios Pharmaceuticals USD -116.87M 10.19M Sep/2025
Amgen USD 3.96B 464M Dec/2025
AstraZeneca USD -1.5B 5.01B Sep/2025
Bayer EUR -543M 556M Sep/2025
BioMarin Pharmaceutical USD -31.69M 308.58M Sep/2025
Bristol-Myers Squibb USD 3.64B 135M Sep/2025
Cytokinetics USD -166.76M 55.25M Sep/2025
Eisai JPY 13.67B 7.07B Sep/2025
Eli Lilly USD 8.39B 1.37B Sep/2025
Exelixis USD 256.36M 42.78M Sep/2025
Genmab DKK 360M 172M Jun/2025
Glaxosmithkline GBP 3.76B 1.32B Sep/2025
Incyte USD 431.31M 120.49M Sep/2025
Ionis Pharmaceuticals USD -160.18M 300.02M Sep/2025
MacroGenics USD 18.64M 55.4M Sep/2025
Merck USD 6.24B 318M Dec/2025
Moderna USD -260M 647M Sep/2025
Neurocrine Biosciences USD 239.3M 93.7M Sep/2025
Novartis USD 4.5B 363M Sep/2025
Pfizer USD 4.65B 3.99B Dec/2025
Sanofi EUR 1.5B 2.29B Dec/2025
Takeda JPY 168.82B 479.89B Dec/2025
Ultragenyx Pharmaceutical USD -170.89M 22.68M Sep/2025
Xencor USD -47.52M 14.35M Sep/2025